Cancer Treatment Monitoring

Current cancer treatments are non targeted and costly

Cancer is a major source of cost and hurt in society, with over 40 million Americans and Europeans living with the disease, and over 4 million new patients diagnosed each year (+10%).

While new treatments are emerging, these are largely non-targeted and costly, ranging from €100’000 to €300’000/patient. Liquid biopsies are a powerful tool to support staging, optimize treatment and follow up, but these are inconclusive in about 35% of cases, due to low specificity of the diagnostic tools used.

Liquid biopsies work by extracting circulating tumor DNA (ctDNA) from blood and sequencing it. Existing extraction technologies deliver low amounts of ctDNA, which results in high sequencing costs, and many inconclusive results.

Our team is developing a ctDNA extraction kit to reduce liquid biopsy costs by about 5x.

Our ctDNA extraction kit is leveraging our patented, proprietary size-selective magnetic beads which extract more ctDNA from cancer samples, enabling:

-Improvement in ctDNA yield vs. current commercialized solution
-Specific selection of only targeted ctDNA and exclusion of the rest
-Reliable results for every sample taken
-Lowest operational cost in cancer diagnosis

We think our ctDNa extraction kit can be the lowest operational cost diagnostic tool to optimize cancer treatments:

-Monitor cancer treatment response in real time with enhanced liquid biopsies
-Detect treatment-resistant cancer gene mutations and predict cancer relapse
-Simplify post-treatment testing for relapse